新华医疗(600587) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was CNY 2,187,552,954.52, a decrease of 6.00% compared to the same period last year[2] - Total profit for the third quarter was CNY 63,978,928.00, down 59.15% year-on-year[2] - Net profit attributable to shareholders was CNY 48,592,929.38, a decline of 63.39% compared to the previous year[2] - The net profit after deducting non-recurring gains and losses for the third quarter was CNY 37,661,492.02, down 71.77% year-on-year[2] - Basic earnings per share for the third quarter were CNY 0.08, down 55.56% year-on-year[2] - Total operating revenue for the first three quarters of 2025 was CNY 6,977,967,842.53, a decrease of 6.0% compared to CNY 7,423,276,804.99 in the same period of 2024[14] - Net profit for the first three quarters of 2025 was CNY 444,084,027.69, a decline of 29.9% compared to CNY 633,953,374.65 in 2024[15] - Earnings per share for the first three quarters of 2025 was CNY 0.72, down from CNY 1.17 in the same period of 2024[15] - The total comprehensive income for the first three quarters of 2025 was CNY 433,285,359.54, compared to CNY 634,016,268.78 in 2024, a decrease of 31.7%[15] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 15,078,842,380.91, a decrease of 2.88% from the end of the previous year[3] - As of September 30, 2025, the total assets of Shandong Xinhua Medical Equipment Co., Ltd. amounted to CNY 15,078,842,380.91, a decrease from CNY 15,526,375,082.77 on December 31, 2024, representing a decline of approximately 2.9%[10] - Current assets totaled CNY 8,969,621,191.24, down from CNY 9,366,020,874.15, indicating a decrease of about 4.2%[11] - The total liabilities decreased to CNY 6,914,349,290.72 in 2025 from CNY 7,543,748,934.23 in 2024, reflecting a reduction of 8.3%[12] - Total equity attributable to shareholders increased by 3.08% to CNY 7,831,135,267.95 compared to the end of the previous year[3] - Total equity increased to CNY 8,164,493,090.19 in 2025, compared to CNY 7,982,626,148.54 in 2024, marking a growth of 2.3%[12] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 219,663,782.82, an increase of 707.49% compared to the previous year[2] - Operating cash flow for the first nine months was ¥219,663,782.82, a significant improvement from a negative cash flow of ¥36,159,027.91 in the same period last year[18] - Total cash inflow from operating activities decreased to ¥6,763,940,456.65, down from ¥7,182,115,065.89 year-over-year[18] - Cash outflow from operating activities also decreased to ¥6,544,276,673.83 compared to ¥7,218,274,093.80 in the previous year[18] - The ending cash and cash equivalents balance was ¥2,617,212,764.15, compared to ¥2,348,299,423.67 at the end of the same period last year[19] Investments and Expenses - The company experienced a significant reduction in other income and investment income, contributing to the decline in profits[6] - Research and development expenses increased to CNY 321,747,889.75 in 2025, up 8.3% from CNY 297,141,310.80 in 2024[14] - The company reported a decrease in sales expenses to CNY 627,531,352.26 in 2025 from CNY 641,583,248.14 in 2024, a reduction of 2.2%[14] - The company’s investment income for the first three quarters of 2025 was CNY 48,281,980.32, down from CNY 52,663,544.58 in 2024, a decline of 8.3%[14] Changes in Specific Accounts - Cash and cash equivalents were reported at CNY 2,751,625,610.03, a decrease from CNY 2,944,731,578.33, reflecting a decline of approximately 6.5%[10] - Accounts receivable increased to CNY 1,966,058,267.66 from CNY 1,879,527,944.98, marking an increase of about 4.6%[10] - Inventory decreased to CNY 3,141,146,365.93 from CNY 3,356,266,390.04, representing a decline of approximately 6.4%[11] - Short-term borrowings increased slightly to CNY 922,118,107.79 from CNY 900,609,472.27, an increase of about 2.8%[11] - Accounts payable decreased to CNY 2,301,442,182.11 from CNY 2,440,735,563.76, indicating a decline of approximately 5.7%[11] - Contract liabilities decreased to CNY 1,756,598,226.89 from CNY 2,049,292,887.66, reflecting a decrease of about 14.3%[11] - Long-term equity investments decreased to CNY 1,416,475,857.93 from CNY 1,506,671,275.58, a decline of approximately 6.0%[11] - The company reported a total non-current asset value of CNY 6,109,221,189.67, slightly down from CNY 6,160,354,208.62, indicating a decrease of about 0.8%[11] Asset Acquisitions and Disposals - The company paid ¥298,226,154.22 for the acquisition of fixed assets, an increase from ¥274,627,509.31 year-over-year[18] - The company reported a cash inflow of ¥99,870,479.75 from the disposal of subsidiaries and other business units[18] - The company received ¥12,405,032.46 from investment recoveries, a decrease from ¥125,983,225.85 in the previous year[18]